Research Initiative Details
A comprehensive overview of TCR expression platform optimization, CRISPR gene editing, and bioinformatic analysis.
TCR Expression Platforms
CRISPR/Cas9
Lentiviral Vectors
Python & R
Flow Cytometry
Aseptic Processing
T Cell Expression Platforms & CRISPR/Cas9 Optimization
Developing high-efficiency TCR expression platforms in primary human T cells using lentiviral vectors, complemented by targeted CRISPR/Cas9 knockouts for cancer immunotherapy.
Engineered recombinant lentiviral vectors to transduce TCR constructs into primary human CD4+ and CD8+ T cells. Applied CRISPR/Cas9 ribonucleoprotein (RNP) complexes to execute site-specific gene edits that enhance immune cell resistance and therapeutic specificity against tumor targets.
Formulated custom Python and R scripts to model and optimize TCR-dextramer binding kinetics, evaluating antigen affinity across primary T cell populations. Analyzed multi-color flow cytometry data to track expansion rates and phenotypic stability.
Processed patient-derived tumor tissue samples under aseptic conditions and maintained long-term lymphocyte cultures. Authored technical documentation and internal reports supporting IND and regulatory submissions for personalized cell therapy trials.